Nerve growth factor and brain-derived neurotrophic factor concentrations in schizophrenia: A review

Journal of Biological Regulators and Homeostatic Agents

Volumn 26, Issue 3, 2012, Pages 347-356

  Martinotti, G ^a   Di Iorio, G ^a   Marini, S ^a   Ricci, V ^a   De Berardis, D ^a   Di Giannantonio, M ^a  

^a UNIVERSITY OF CHIETI   (Italy)

Author keywords

Brain derived neurotrophic factor (BDNF); Nerve growth factor (NGF); Schizophrenia

Indexed keywords

4 AMINOBUTYRIC ACID RECEPTOR; AMISULPRIDE; BRAIN DERIVED NEUROTROPHIC FACTOR; BROMPERIDOL; CHLORPROMAZINE; CLOZAPINE; DOPAMINE RECEPTOR; HALOPERIDOL; INTERLEUKIN 2; LEVOMEPROMAZINE; NERVE GROWTH FACTOR; NEUROTROPHIN 3; NEUROTROPHIN 4; OLANZAPINE; PERPHENAZINE; RISPERIDONE; SEROTONIN RECEPTOR; TRIFLUOPERAZINE; ZOTEPINE;

BRAIN DEVELOPMENT; BRAIN FUNCTION; BRAIN SIZE; CLINICAL ASSESSMENT; COGNITIVE DEFECT; DIAGNOSTIC ACCURACY; DNA POLYMORPHISM; DOPAMINERGIC NERVE CELL; ELECTROCONVULSIVE THERAPY; GENE EXPRESSION; GENETIC ASSOCIATION; HIPPOCAMPUS; HUMAN; LANGUAGE DISABILITY; MENTAL PATIENT; NERVE CELL PLASTICITY; PARANOID SCHIZOPHRENIA; PATHOPHYSIOLOGY; PROGNOSIS; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; PROTEIN FUNCTION; REVIEW; SCHIZOPHRENIA; SIGNAL TRANSDUCTION; SMOKING;

ANTIPSYCHOTIC AGENTS; BIOLOGICAL MARKERS; BRAIN-DERIVED NEUROTROPHIC FACTOR; HIPPOCAMPUS; HUMANS; NERVE GROWTH FACTOR; SCHIZOPHRENIA;

EID: 84868124883     PISSN: 0393974X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (46)

1. Durany N, Thome J. Neurotrophic factors and the pathophysiological of schizophrenic psychoses. Eur Psychiatry 2004; 19(6):326-37. (Pubitemid 39207958)
2. Shoval G, Weizman A. The possible role of neurotrophins in the pathogenesis and therapy of schizophrenia. Eur Neuropsychopharmacol 2005; 15(3):319-29. (Pubitemid 40487736)
3. Sofroniew MV, Howe CL, Mobley WC. Nerve growth factor signaling, neuroprotection, and neural repair. Annu Rev Neurosci 2001; 24:1217-81. (Pubitemid 32695259)
4. Maness LM, Kastin AJ, Weber JT, Banks WA, Beckman BS, Zadina JE. The neurotrophins and their receptors: structure, function, and neuropathology. Neurosci Biobehav Rev 1994; 18(1):143-59. (Pubitemid 24058931)
5. Bramham CR, Messaoudi E. BDNF function in adult synaptic plasticity: the synaptic consolidation hypothesis. Prog Neurobiol 2005; 76(2):99-125. (Pubitemid 41242884)
6. Thoenen H. Neurotrophins and neuronal plasticity. Science 1995; 270(5236):593-8.
7. Castren E. Is mood chemistry? Nat Rev Neurosci 2005; 6(3):241-6. (Pubitemid 40342418)
8. Spalletta G, Morris DW, Angelucci F, et al. BDNF Val66Met polymorphism is associated with aggressive behavior in schizophrenia. Eur Psychiatry 2010; 25(6):311-3.
9. Ansorge MS, Hen R, Gingrich JA. Neurodevelopmental origins of depressive disorders. Curr Opin Pharmacol 2007; 7(1):8-17. (Pubitemid 46238045)
10. Takahashi M, Shirakawa O, Toyooka K, et al. Abnormal expression of brain-derived neurotrophic factor and its receptor in the corticolimbic system of schizophrenic patients. Mol Psychiatry 2000; 5(3):293-300. (Pubitemid 30438405)
11. Muglia P, Vicente AM, Verga M, King N, Macciardi F, Kennedy JL. Association between the BDNF gene and schizophrenia. Mol Psychiatry 2003; 8(2): 146-7.
12. Spence SA, Hirsch SR, Brooks DJ, Grasby PM. Prefrontal cortex activity in people with schizophrenia and control subjects. Evidence from positron emission tomography for remission of 'hypofrontality' with recovery from acute schizophrenia. Br J Psychiatry 1998; 172:316-23. (Pubitemid 28183857)
13. Aloe L, Iannitelli A, Bersani G, Alleva E, Angelucci F, Maselli P, Manni L. Haloperidol administration in humans lowers plasma nerve growth factor level: evidence that sedation induces opposite effects to arousal. Neuropsychobiology 1997; 36(2):65-8. (Pubitemid 27331262)
14. Jockers-Scherübl MC, Matthies U, Danker-Hopfe H, Lang UE, Mahlberg R, Hellweg R. Chronic cannabis abuse raises nerve growth factor serum concentrations in drug-naive schizophrenic patients. J Psychopharmacol 2003; 17(4):439-45. (Pubitemid 38076340)
15. Martinotti G, Carli V, Tedeschi D, Di Giannantonio M, Roy A, Janiri L, Sarchiapone M. Mono- and polysubstance dependent subjects differ on social factors, childhood trauma, personality, suicidal behaviour, and comorbid Axis I diagnoses. Addict Behav 2009; 34(9):790-3.
16. Parikh V, Evans DR, Khan MM, Mahadik SP. Nerve growth factor in never-medicated first-episode psychotic and medicated chronic schizophrenic patients: possible implications for treatment outcome. Schizophr Res 2003; 60(2-3):117-23. (Pubitemid 36187455)
17. Shcherbakova IV, Siryachenko TM, Mazaeva NA, Kaleda VG, Krasnolobova SA, Klyushnik TP. Leukocyte elastase and autoantibodies to nerve growth factor in the acute phase of schizophrenia and their relationship to symptomatology. World J Biol Psychiatry 2004; 5(3):143-8. (Pubitemid 44121708)
18. Bersani G, Iannitelli A, Massoni E, Garavini A, Grilli A, Di Giannantonio M, Conti CM, Pancheri P. Ultradian variation of nerve growth factor plasma levels in healthy and schizophrenic subjects. Int J Immunopathol Pharmacol 2004; 17(3):367-72. (Pubitemid 39481679)
19. Kale A, Joshi S, Pillai A, Naphade N, Raju M, Nasrallah H, Mahadik SP. Reduced cerebrospinal fluid and plasma nerve growth factor in drug-naive psychotic patients. Schizophr Res 2009; 115(2-3):209-14.
20. Xiong P, Zeng Y, Wan J, Xiaohan DH, Tan D, Lu J, Xu F, Li HY, Zhu Z, Ma M. The role of NGF and IL-2 serum level in assisting the diagnosis in first episode schizophrenia. Psychiatry Res 2011; 189(1):72-6.
21. De Berardis D, Conti CM, Serroni N, Moschetta FS, Olivieri L, Carano A, Salerno RM, Cavuto M, Farina B, Alessandrini M, Janiri L, Pozzi G, Di Giannantonio M. The effect of newer Serotoninnoradrenalin antidepressants on cytokine production: a review of the current literature. Int J Immunopathol Pharmacol 2010; 23(2):417-22.
22. Lee BH, Kim YK. Increased plasma brain-derived neurotropic factor, not nerve growth factor-Beta, in schizophrenia patients with better response to risperidone treatment. Neuropsychobiology 2009; 59(1):51-8.
23. Pirildar S, Gönül AS, Taneli F, Akdeniz F. Low serum levels of brain-derived neurotrophic factor in patients with schizophrenia do not elevate after antipsychotic treatment. Prog Neuropsychopharmacol Biol Psychiatry 2004; 28(4):709-13. (Pubitemid 38987396)
24. Buckley PF, Pillai A, Evans D, Stirewalt E, Mahadik S. Brain derived neurotropic factor in first-episode psychosis. Schizophr Res 2007; 91(1-3): 1-5.
25. Pillai A, Kale A, Joshi S, Naphade N, Raju MS, Nasrallah H, Mahadik SP. Decreased BDNF levels in CSF of drug-naive first-episode psychotic subjects: correlation with plasma BDNF and psychopathology. Int J Neuropsychopharmacol 2010; 13(4):535-9.
26. Green MJ, Matheson SL, Shepherd A, Weickert CS, Carr VJ. Brain-derived neurotrophic factor levels in schizophrenia: a systematic review with metaanalysis. Mol Psychiatry 2010; 6(9):960-72.
27. Lee AH, Lange C, Ricken R, Hellweg R, Lang UE. Reduced brain-derived neurotrophic factor serum concentrations in acute schizophrenic patients increase during antipsychotic treatment. J Clin Psychopharmacol 2011; 31(3):334-6.
28. Tan YL, Zhou DF, Zhang XY. Decreased plasma brain-derived neurotrophic factor levels in schizophrenic patients with tardive dyskinesia: association with dyskinetic movements. Schizophr Res 2005; 74(2-3):263-70. (Pubitemid 40255082)
29. Xiu MH, Hui L, Dang YF, et al. Decreased serum BDNF levels in chronic institutionalized schizophrenia on long-term treatment with typical and atypical antipsychotics. Prog Neuropsychopharmacol Biol Psychiatry 2009; 33(8):1508-12.
30. Shimizu E, Hashimoto K, Watanabe H, et al. Serum brain-derived neurotrophic factor (BDNF) levels in schizophrenia are indistinguishable from controls. Neurosci Lett 2003; 351(2):111-4. (Pubitemid 37329601)
31. Rizos EN, Michalopoulou PG, Siafakas N, et al. Association of serum brain-derived neurotrophic factor and duration of untreated psychosis in first-episode patients with schizophrenia. Neuropsychobiology 2010; 62(2):87-90.
32. Zhang XY, Tan YL, Zhou DF, et al. Serum BDNF levels and weight gain in schizophrenic patients on long-term treatment with antipsychotics. J Psychiatr Res 2007; 41(12):997-1004. (Pubitemid 47304448)
33. Toyooka K, Asama K, Watanabe Y, Muratake T, Takahashi M, Someya T, Nawa H. Decreased levels of brain-derived neurotrophic factor in serum of chronic schizophrenic patients. Psychiatry Res 2002; 110(3):249-57. (Pubitemid 34804533)
34. Grillo RW, Ottoni GL, Leke R, Souza DO, Portela LV, Lara DR. Reduced serum BDNF levels in schizophrenic patients on clozapine or typical antipsychotics. J Psychiatr Res 2007; 41(1-2):31-5. (Pubitemid 44708213)
35. Ikeda Y, Yahata N, Ito I, Nagano M, Toyota T, Yoshikawa T, Okubo Y, Suzuki H. Low serum levels of brain-derived neurotrophic factor and epidermal growth factor in patients with chronic schizophrenia. Schizophr Res 2008; 101(l-3):58-66.
36. Reis HJ, Nicolato R, Barbosa IG, Teixeira do Prado PH, Romano-Silva MA, Teixeira AL. Increased serum levels of brain-derived neurotrophic factor in chronic institutionalized patients with schizophrenia. Neurosci Lett 2008; 439(2):157-9.
37. Chen CC, Huang TL. Effects of antipsychotics on the serum BDNF levels in schizophrenia. Psychiatry Res 2011; 189(3):327-30.
38. Pedrini M, Chendo I, Grande I, et al. Serum brain-derived neurotrophic factor and clozapine daily dose in patients with schizophrenia: a positive correlation. Neurosci Lett 2011; 491(3):207-10.
39. Hori H, Yoshimura R, Yamada Y, Ikenouchi A, Mitoma M, Ida Y, Nakamura J. Effects of olanzapine on plasma levels of catecholamine metabolites, cytokines, and brain-derived neurotrophic factor in schizophrenic patients. Int Clin Psychopharmacol 2007; 22(1):21-7. (Pubitemid 44950764)
40. Gama CS, Andreazza AC, Kunz M, Berk M, Belmonte-de-Abreu PS, Kapczinski F. Serum levels of brain-derived neurotrophic factor in patients with schizophrenia and bipolar disorder. Neurosci Lett 2007; 420(1):45-8. (Pubitemid 46777098)
41. Martinotti G, Ricci V, Di Nicola M, Caltagirone C, Bria P, Angelucci F. Brain-derived neurotrophic factor and electroconvulsive therapy in a Schizophrenic patient with treatment-resistant paranoid-hallucinatory symptoms. J ECT 2011; 27(1):e44-6.
42. Rüsch N, Spoletini I, Wilke M, Martinotti G, Bria P, Trequattrini A, Bonaviri G, Caltagirone C, Spalletta G. Inferior frontal white matter volume and suicidality in schizophrenia. Psychiatry Res 2008; 164(3):206-14.
43. Jockers-Scherübl MC, Danker-Hopfe H, Mahlberg R, Selig F, Rentzsch J, Schürer F, Lang UE, Hellweg R. Brain-derived neurotrophic factor serum concentrations are increased in drug-naive schizophrenic patients with chronic cannabis abuse and multiple substance abuse. Neurosci Lett 2004; 371(1):79-83. (Pubitemid 39410519)
44. Zhang XY, Xiu MH, Chen da C, Yang FD, Wu GY, Lu L, Kosten TA, Kosten TR. Nicotine dependence and serum BDNF levels in male patients with schizophrenia. Psychopharmacology (Berl) 2010; 212(3):301-7.
45. Huang TL, Lee CT. Associations between serum brain-derived neurotrophic factor levels and clinical phenotypes in schizophrenia patients. J Psychiatr Res 2006; 40(7):664-8.
46. Marini A, Spoletini I, Rubino IA, et al. The language of schizophrenia: an analysis of micro and macrolinguistic abilities and their neuropsychological correlates. Schizophr Res 2008; 105(1-3):144-55.